Poster Pearl: A 2-Biomarker Class MCED Test Delivers High Specificity and Sensitivity
Brian P. McDonough, MD, FAAFP
Frank Diehl, PhD
Hepatocellular Carcinoma: Examining Its Prevalence and Prognostic Biomarkers
Hepatocellular Carcinoma: Reducing Barriers in Diagnosis and Treatment
Future Directions: Targeting LAG-3 in Melanoma Treatment
Hussein Tawbi, MD, PhD
Navigating Treatment-Related Adverse Effects in LAG-3 Combination ICI Therapy for Metastatic Melanoma
Allison Betof Warner, MD, PhD
Patient Case: Tailoring First-Line Treatment for a Patient With Metastatic Melanoma and Impaired Performance Status
Unlocking Synergy: Exploring the Interaction Between LAG-3 and Other Immune Checkpoints
Optimizing Therapeutic Selection for a Patient With Newly Diagnosed BRAF V600e-Mutated Metastatic Melanoma
Analyzing Key Data from LAG-3 Combinations in the Treatment of Metastatic Melanoma
Leveraging LAG-3: Innovative Immunotherapy Combinations for First-Line Metastatic Melanoma Treatment
First-Line Treatment of Metastatic Melanoma After Adjuvant Anti-PD-1
Integrating Clinical Insights: Key G/GEJ Cancer Data Analyzed from the San Diego Oncology Conference
Samuel J. Klempner, MD
Navigating Treatment Paths: Selection and Sequencing in Biomarker-Driven Combination Regimens for First-Line G/GEJ Cancer Therapy
Yelena Janjigian, MD
Optimizing Treatment of Metastatic G/GEJ Cancers: Balancing Efficacy and Adverse Effects With Combination Regimens
How Can a Multidisciplinary Team Optimize Management of G/GEJ Cancer–Related Symptom Burden?
Navigating CLL Treatment: A Deep Dive into Efficacy and Safety
John Russell, MD
Seema A. Bhat, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We’re glad to see you’re enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.